Mcdaniel Terry & Co. Sells 2,250 Shares of Novartis AG (NYSE:NVS)

Mcdaniel Terry & Co. lessened its position in Novartis AG (NYSE:NVS) by 36.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,940 shares of the company’s stock after selling 2,250 shares during the period. Mcdaniel Terry & Co.’s holdings in Novartis were worth $383,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Legacy Investment Solutions LLC bought a new stake in Novartis in the 3rd quarter worth $28,000. Human Investing LLC purchased a new stake in shares of Novartis in the 4th quarter worth about $25,000. Union Bancaire Privee UBP SA purchased a new stake in shares of Novartis in the 4th quarter worth about $27,000. Fortitude Family Office LLC lifted its position in shares of Novartis by 503.8% in the 3rd quarter. Fortitude Family Office LLC now owns 320 shares of the company’s stock worth $37,000 after purchasing an additional 267 shares during the period. Finally, Kestra Investment Management LLC purchased a new stake in shares of Novartis in the 4th quarter worth about $47,000. Institutional investors own 13.12% of the company’s stock.

Novartis Stock Up 0.4 %

Shares of Novartis stock opened at $107.06 on Thursday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.84 and a current ratio of 1.04. The stock has a market capitalization of $218.82 billion, a PE ratio of 18.21, a price-to-earnings-growth ratio of 1.69 and a beta of 0.58. Novartis AG has a 52-week low of $92.35 and a 52-week high of $120.92. The company has a 50-day simple moving average of $100.91 and a two-hundred day simple moving average of $108.16.

Novartis (NYSE:NVS) last issued its earnings results on Friday, January 31st. The company reported $1.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.24%. On average, analysts anticipate that Novartis AG will post 8.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

NVS has been the subject of several research analyst reports. HSBC cut shares of Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. BMO Capital Markets lifted their price target on shares of Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a research report on Wednesday, October 30th. Erste Group Bank reissued a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. StockNews.com raised shares of Novartis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 8th. Finally, Morgan Stanley initiated coverage on shares of Novartis in a research report on Wednesday, February 12th. They set an “underweight” rating for the company. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $123.38.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.